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Developmental transitions are guided by master regulatory tran-
scription factors. During adipogenesis, a transcriptional cascade
culminates in the expression of PPARγ and C/EBPα, which orches-
trate activation of the adipocyte gene expression program. How-
ever, the coactivators controlling PPARγ and C/EBPα expression
are less well characterized. Here, we show the bromodomain-
containing protein, BRD4, regulates transcription of PPARγ and
C/EBPα. Analysis of BRD4 chromatin occupancy reveals that induc-
tion of adipogenesis in 3T3L1 fibroblasts provokes dynamic redis-
tribution of BRD4 to de novo super-enhancers proximal to genes
controlling adipocyte differentiation. Inhibition of the bromodomain
and extraterminal domain (BET) family of bromodomain-containing
proteins impedes BRD4 occupancy at these de novo enhancers and
disrupts transcription of Pparg and Cebpa, thereby blocking adipo-
genesis. Furthermore, silencing of these BRD4-occupied distal regula-
tory elements at the Pparg locus by CRISPRi demonstrates a critical
role for these enhancers in the control of Pparg gene expression and
adipogenesis in 3T3L1s. Together, these data establish BET bromodo-
main proteins as time- and context-dependent coactivators of the
adipocyte cell state transition.
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Transcription factors (TFs) guide cell state transitions duringdevelopment (1). Adipocyte differentiation is controlled
by the action of peroxisome proliferator-activated receptor
gamma (PPARγ) and CCAAT/enhancer binding protein alpha
(C/EBPα), master TFs that control the gene expression program
of the developing adipocyte (2). In model systems, proadipogenic
stimuli induce PPARγ and C/EBPα expression by activating an
upstream TF cascade comprised of C/EBPβ, C/EBPδ, and the
glucocorticoid receptor (GR) (3). Disruption of this TF network
impairs adipocyte differentiation and adipose tissue formation (4).
These master TF networks signal via chromatin to execute the
gene expression programs that drive adipogenesis. Comparative
analysis of chromatin states in preadipocytes versus adipocytes
has demonstrated massive enhancer reorganization during adi-
pogenesis, as marked by genome-wide changes in the acetylation
of histone 3 lysine 27 (H3K27ac) or lysine 9 (H3K9ac) (5, 6).
Super-enhancers—cis-regulatory domains comprised of dense
clusters of DNA-bound TFs and exceptionally high enrichment
of chromatin-associated coactivators [e.g., BRD4, Mediator
subunit-1 (MED1)]—have recently been identified in models of
adipogenesis (7). Super-enhancers, akin to stretch enhancers or
locus control regions, contain a disproportionately large amount
of coactivator molecules for any given cell state (8, 9) and drive
transcription of genes essential for cell identity (10, 11). During
adipogenesis, super-enhancers have been identified near genes
important for adipocyte differentiation including Pparg (7). How-
ever, the specific mechanisms by which dynamically remodeled
enhancers signal to RNA polymerase and regulate adipogenesis are
not as well characterized.
The bromodomain and extraterminal domain (BET) family of
bromodomain-containing coactivator proteins—BRD2, BRD3,
BRD4—associate with chromatin (12–14). BETs coactivate tran-
scription by forming scaffolds with other coregulatory proteins,
including Mediator subunits and the positive transcription elon-
gation factor-b (PTEF-b) complex at enhancers. These multi-
protein complexes activate RNA polymerase II (RNA Pol II) via
long-range chromatin interactions (15). Prior studies establish
BRD4 as a dynamic constituent of super-enhancers (10, 16, 17).
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Recently, a distinct role for BETs has been described in tran-
scription control of dynamic, stimulus-coupled cell state transi-
tions in heart failure and inflammation (18, 19). Overall, these
data reveal that BETs can transduce dynamic, genome-wide
changes in enhancer activity to regulate cell identity.
We hypothesized that BETs are essential coregulators of
adipogenesis. Here, we show that BRD4 is a critical enhancer
factor that potently coactivates stage-specific expression of
PPARγ and C/EBPα during adipogenesis. Induction of adipo-
genesis in 3T3L1 preadipocytes provokes dynamic redistribution
of BRD4 to de novo super-enhancer regions including the cis-
regulatory elements controlling transcription of PPARγ and
C/EBPα, thereby promoting differentiation. Displacement of
BRD4 from enhancer chromatin with a BET bromodomain
inhibitor blocks transcription of Pparg resulting in failure of
differentiation. These data establish BET bromodomain proteins
as essential transcriptional coactivators of the adipocyte cell state
transition and implicate BET proteins in the regulation of sys-
temic metabolic processes.
Results
BET Bromodomain Proteins Control Adipocyte Differentiation. We
first tested the effect of BET bromodomain inhibition on adipo-
cyte differentiation using the 3T3L1 murine fibroblast model
system (“L1”). Induction of differentiation using dexamethasone,
isobutylmethylxanthine (IBMX), and insulin (DMI) resulted in
adipocyte differentiation on day 8, as reflected by uniform lipid
accumulation measured by oil red O staining (Fig. 1A). Cotreat-
ment of preadipocytes with a panel of structurally dissimilar BET
bromodomain inhibitors blocked differentiation (Fig. 1A) (20–24).
Effects on adipogenesis correlated with their relative IC50 against
BRD4 (25). PFl-1 demonstrated a more modest block in adipo-
genesis, while RVX-208 demonstrated no difference at the con-
centration tested (1 μM) (Fig. 1A and Fig. S1A). Inhibition of
L1 differentiation by JQ1 was concentration-dependent, occurred
without significant cytotoxicity, and resulted in only a modest
slowing of cell cycle (Fig. S1 B and C).
Given these potent effects of BET bromodomain inhibition on
adipogenesis, we next considered the role of BETs in gene reg-
ulation during differentiation. To address this issue, we designed
a gene expression probe set (58 probes) for digital mRNA
analysis (Nanostring). This curated gene set, containing probes
for measuring expression of proadipogenic TFs, key transcrip-
tional coregulators, and mature adipocyte markers, represents a
molecular signature that encompasses critical stages of the dif-
ferentiation process. At day 4 of L1 differentiation, we observed
expected induction of master regulatory TFs including Cebpa,
Pparg, members of the Klf family, and retinoid-x receptor family
(Rxr) as well as downstream target genes involved in adipocyte
function including lipid uptake (Cd36; fatty acid binding protein:
Fabp4), lipid synthesis (monoacylglyerol lipase: Magl; diac-
ylglycerol O-actyltransferase1: Dgat1), and systemic metabolism
(Adipsin; Adipoq) (Fig. 1 B and C). Cotreatment of L1s with
JQ1 abrogated induction of the adipocyte gene set (Fig. 1 B and
C), and unsupervised hierarchical clustering grouped JQ1-
treated L1s more closely with preadipocytes. Both Pparg and
Cebpa mRNA levels were quantitatively similar to preadipocytes
(Fig. S1 D and E). BET inhibition also suppressed induction of
Adipoq and Fabp4, two genes directly regulated by PPARγ (Fig.
S1 F and G). Complementary studies using siRNA-mediated
knockdown of Brd4 supported a role for this BET family mem-
ber in L1 differentiation (Fig. S1 H and I). To explore the rel-
evance of these findings in primary cells, we next performed
adipocyte differentiation assays using the stromal vascular frac-
tion (SVF) isolated from murine subcutaneous (s.c.) adipose
depots. Cells from SVF differentiated into mature adipocytes
over 10 d in the presence of a defined hormonal mixture.
Concomitant BET bromodomain inhibition resulted in a
concentration-dependent block in differentiation (Fig. 1D). In
rodents, a short period of visceral adipose tissue expansion oc-
curs in the first weeks of postnatal life, which may, in part, be
regulated by adipogenesis (26). To test the role of BET bro-
modomain proteins in adipose tissue, we treated 2-wk-old pups
with JQ1 for 12 d and detected a significant reduction in epi-
didymal white adipose tissue (EWAT) mass (Fig. S1J). In
EWAT, Pparg2 mRNA levels were also lower in JQ1-treated
animals. Taken together, these data establish a role for BET
bromodomain proteins in adipocyte differentiation in both the
L1 model system and primary mouse adipogenic precursors.
BETs Control Expression of the Master TFs Pparg and Cebpa. A pre-
cise, temporally regulated cascade of TF activity drives adipo-
genesis. Consistent with this wave of TF function, we observed a
time-dependent effect of BET bromodomain inhibition on L1
differentiation. JQ1 cotreatment on day 2 or day 4 after in-
duction of differentiation resulted in significant reductions in
lipid accumulation and Pparγ, Cebpα and Adipoq gene expres-
sion, with these inhibitory effects diminishing when JQ1 was
administered at later time points in the differentiation process
(Fig. 2 A and C and Fig. S2A). JQ1 treatment of fully differen-
tiated adipocytes (day 6) had no effect on Pparg and Cebpa gene
expression or the mature adipocyte phenotype measured on day
8. We next tested whether JQ1 effects were reversible during this
first 96-h window by performing JQ1 washout experiments. As
before, JQ1 treatment throughout the 8 d completely blocked
L1 differentiation (Fig. S2B). JQ1 exposure during day 0 through
day 2 also suppressed differentiation and Pparg expression, but
partial recovery of expression did occur. This recovery was more
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Fig. 1. BET bromodomain proteins control adipocyte differentiation. (A) Pho-
tomicrographs of oil red O stained L1 adipocytes after induction of differenti-
ation by DMI (day 8) ± structurally distinct BET bromodomain inhibitors (JQ1 at
500 nM; I-BET, I-BET-151, and PFI-1 at 1 μM). (B and C) Heatmaps of expression
of proadipogenic, master regulators (B), and mature adipocyte genes (C) at
D0 and D4 of differentiation ± JQ1 (500 nM). (D) Photomicrographs of oil red
O staining after differentiation of cells isolated from the stromal vascular
fraction of mouse s.c. adipose tissue ± JQ1. Data represent mean ± SEM. The
statistical significance of the difference in expression between vehicle (VEH)
and JQ1 was determined using a two-tailed t test. (Magnification: 4×.)








evident in cells exposed to BET inhibition for only 24 h between
D1 and D2 (Fig. S2 B and C).
Adipogenesis proceeds in two phases: (i) early fate specification,
involving commitment of stem cells to the adipocyte lineage, and
(ii) terminal differentiation, in which committed cells progressively
acquire features of mature adipocyte phenotype (3). As L1 cells are
already committed to the adipocyte lineage (3), we asked whether
BETs also played a role in the earlier events of lineage specifica-
tion. Therefore, we performed an additional series of differentia-
tion experiments with C3H10T1/2 cells (10T1/2), a cell line derived
from the C3H mouse embryo that possesses mesenchymal stem
cell-like properties and can be induced to differentiate into adi-
pocytes using a hormonal mixture (27). In the 10T1/2 model, ma-
ture adipocytes are evident by day 4. Similar to our L1 experiments,
BET inhibition blocked differentiation in 10T1/2 cells in a time-
dependent manner (Fig. 2 B and D and Fig. S2D). Reductions in
Pparg expression persisted in the presence of BET inhibition
whether initiated on day 0 or day 2 of differentiation, while Cebpa
mRNA levels were similar to vehicle in day 2-treated cells (Fig. 2D).
In contrast to BRD4 loss-of-function experiments, enforced
expression of BRD4 in NIH3T3s—a nonadipogenic cell line—did
not induce differentiation (Fig. S2E), consistent with a role for
BRD4 as a coactivaor that transduces signals from enhancer-bound
TFs to the transcriptional machinery. Collectively, these data es-
tablish that BETs are stage-specific regulators of adipocyte differ-
entiation and Pparg expression in committed preadipocytes (L1)
and mesenchymal stem cells (10T1/2), but BRD4 is not sufficient to
drive differentiation in cells lacking intrinsic adipogenic potential.
L1 differentiation proceeds by the coordinated action of a TF
cascade that converges on Pparg and Cebpa expression. We next
tested whether BET bromodomain proteins regulate the first
wave of master TF expression during adipogenesis. In time-
course experiments, expression of Krox20, Klf5, Cebpb, and
Cebpd increased 1 h after starting L1 differentiation, peaked by
6 h, and returned to baseline by 24–48 h (Fig. 2E). Cotreatment
of L1 cells with JQ1 had no effect on the magnitude or kinetics
of Krox20, Cebpb, or Cepbd regulation, with a modest effect on
Klf5 mRNA levels. Despite no significant effects on the expres-
sion of these early TFs, BET inhibition completely abolished
induction of both Cebpa and Pparg. In addition, treatment of
L1 cells with a high-affinity, synthetic PPARγ ligand (rosiglita-
zone, 1 μM) that further drives adipogenesis also failed to rescue
the block in differentiation by BET bromodomain inhibition
(Fig. 2F and Fig. S2F). Overall, these data support a model in
which BET bromodomain proteins promote adipocyte differen-
tiation by coactivating expression of Pparg and Cebpa in a cell
type-specific manner.
BRD4 Is Dynamically Redistributed to Proadipogenic Super Enhancers.
To determine the role of BETs in adipocyte enhancer function,
we first investigated genome-wide BRD4 binding to chromatin in
L1 preadipocytes (day 0, “D0”) and differentiating adipocytes
(day 2, “D2”) using chromatin immunoprecipitation coupled
with high-throughput deep sequencing (ChIP-seq). Experimental
data obtained for BRD4 were integrated with publicly available
datasets that provide high-resolution epigenomic maps of eu-
chromatin during adipocyte differentiation (5). First, we identi-
fied BRD4 to be enriched at preadipocyte and adipocyte promoters
(13% and 4%, respectively, and as follows) and intergenic (39% and
38%) and intragenic (47% and 57%) regulatory sequences (Fig.
S3A). Alignment of BRD4 ChIP-seq data with published chromatin
state maps of enhancers (H3K27ac) and promoters (H3K4me3) in
L1 cells demonstrated a strong correlation between H3K27ac and
BRD4 at both D0 and D2 (Fig. S3B). Global alignment revealed
BRD4 localized to chromatin at promoters and enhancers in both
preadipocytes and adipocytes (Fig. S3C).
We next ranked BRD4 enhancers by increasing ChIP-seq
signal and identified 212 and 411 super-enhancers in pre-
adipocytes and adipocytes, respectively (Fig. 3 A and B). Dif-
ferences in super-enhancer regions between preadipocytes and
adipocytes (Fig. 3 A and B) prompted a systematic evaluation of
the dynamic changes in super-enhancer organization. We ob-
served significant redistribution of BRD4 to new enhancers in
the D2-differentiating adipocytes. Differential enhancer analysis
reclassified a significant subset of enhancers as transitioning
from typical to super-enhancer (“adipocyte-gained,” n = 365)
and from super to typical enhancer (“preadipocyte-lost,” n = 54)
(Fig. 3C). Genes associated with adipocyte-gained super-
enhancers were enriched for TFs that positively regulate adipo-
cyte differentiation, including Pparg, Cebpa, and Cebpb (Fig. 3C).
In contrast, other genes associated with preadipocyte-lost super-
enhancers, such as Klf3 and Pleotrophin (Ptn), are known to
interfere with differentiation and are down-regulated during
adipogenesis; furthermore, prior work has revealed that enforced
expression of these factors suppresses differentiation (28, 29).
Super-enhancers feature high levels of coactivator protein en-
richment and are also densely occupied by master regulatory
TFs (8). Motif analysis revealed the GR (NR3C1) and C/EBP
motifs were found at much higher density at adipocyte-gained
super-enhancer regions compared with preadipocyte-lost super-
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Fig. 2. BETs control expression of the master TFs Pparg and Cebpa. (A and B)
Photomicrographs oil red O stained L1s (A) or C3H10T1/2 mesenchymal stem
cells (B) after induction of differentiation ± JQ1 (500 nM). JQ1 was added to
differentiation medium on indicated days. Staining was on D6 for L1 and
D4 for 10T1/2. (Magnification: 4×.) (C and D) Bar plots of fold change in Pparg
and Cebpa mRNA levels in 3T3L1 cells and 10T1/2 cells from A and B. ns, not
significant. (E) Line plots of fold change in mRNA of early response TFs in-
volved in adipogenesis measured at 1, 6, 24, 48, and 96 h following induction
of differentiation ± JQ1 (500 nM). (F) Oil red O staining of L1 adipocytes 8 d
after induction of differentiation in the presence or absence of rosiglitazone
(1 μM) ± JQ1 (500 nM). (Magnification: 10×.) Data represent mean ± SEM. The
statistical significance of the difference in expression between vehicle (VEH)
and JQ1 at each time point in C and Dwas determined using one-way ANOVA
with post hoc (Dunnett’s) multiple comparison tests of the means. **P < 0.01,
***P < 0.001. For E, two-way ANOVA was performed with ***P < 0.001 for
interaction comparing time x treatment groups.
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enrichment between BRD4 and previously generated datasets for
C/EBPβ, CEBPδ, GR, and PPARγ ChIP-seq also demonstrated
strong statistical correlation at D2 of L1 differentiation between
each of these TFs and BRD4 (R2 = 0.58, 0.62, 0.43, 0.57, re-
spectively) (Fig. 3 F and G and Fig. S3D), suggesting genomic
colocalization of these factors. In addition, coimmunoprecipita-
tion experiments revealed a modest interaction between CEBPβ
and BRD4 during differentiation (Fig. S3E), as previously iden-
tified in other cell types (13, 14). At the Pparg locus, pre-
adipocytes feature minimal BRD4 or H3K27ac enrichment (Fig.
3H). Following induction of differentiation, L1 cells on D2 acquired
massive increases in both BRD4 and H3K27ac levels at a 5′ distal
regulatory element and the promoter region of Pparg, consistent
with formation of super-enhancers (Fig. 3H). By contrast, the Ptn
locus contained high levels of BRD4 and H3K27ac at the 5′ en-
hancer region in preadipocytes, which were lost on D2 of differen-
tiation (Fig. 3I). To test the signals that control recruitment of
BRD4 to chromatin, we omitted individual components of the ad-
ipocyte differentiation mixture. The absence of insulin in this mix-
ture resulted in a reduction of BRD4 recruitment to the Pparg locus
after 24 h of differentiation (Fig. 4 and Fig. S3F). Overall, these
results establish that BRD4 dynamically redistributes away from
preadipocyte genes to new super-enhancers associated with stage-
specific expression of master regulatory factors including proadi-
pogenic TFs such as Pparg.
BRD4 Super-Enhancer Binding Sites Regulate Pparg Gene Expression
and Adipogenesis. Recruitment of BRD4 to super-enhancers at
the Pparg locus suggests that these cis-regulatory elements may
directly control Pparg gene expression. To test this hypothesis, we
employed clustered, regularly interspaced, palindromic repeats
interference (CRISPRi) to silence individual cis-regulatory ele-
ments occupied by BRD4 (30). L1 cells were selected for stable
expression of dCas9-KRAB along with individual guide RNAs
(gRNAs) complementary to DNA at BRD4-enriched loci within
the Pparg super-enhancers (Figs. 3H and 4). Targeting these sites
by multiple, individual gRNAs repressed Pparg gene induction on
D4 of L1 differentiation, compared with cells expressing dCas9-
KRAB with no gRNA (Fig. 4). Notably, silencing of the distal 5′
site (E1) and intragenic sites (E4, E5) resulted in the most sig-
nificant reduction in gene expression, with more modest effects at
the other regions tested. CRISPRi of these Pparg enhancers also
attenuated adipogenesis, as measured by oil red O staining (Fig.
4B). These data establish an important functional role for these de
novo formed, BRD4-enriched cis-regulatory elements in adipo-
genesis in the endogenous chromatin context of the cell.
Transcription of Pparg and Cebpa Is BET Bromodomain-Dependent.
The dynamic redistribution of BRD4 to de novo super-enhancers
predicts that depletion of BRD4 from chromatin would reduce
transcription at super enhancer-associated genes. To analyze the
transcriptional consequences of disruption of BET super-
enhancers, we performed ChIP-seq analysis of RNA Pol II oc-
cupancy in L1 preadipocytes (D0) as well as differentiating
L1s (D2) in the presence or absence of the selective BET bro-
modomain inhibitor (JQ1, 500 nM). Comparison of RNA Pol II
signal from actively transcribed genes in vehicle versus JQ1-
treated L1s revealed overall statistical correlation between these
two groups (Fig. 5A). However, at a subset of genes, RNA Pol II
signal in JQ1-treated cells was lower than vehicle (Fig. 5A).
Within this cluster, reductions in RNA Pol II signal at the Pparg
gene locus were noted in JQ1-treated L1 cells. A comparison of
RNA Pol II signal at the Pparg and Cebpa loci on D0 versus
D2 revealed a robust increase during differentiation, coincident
with acquisition of BRD4 at super-enhancers (Figs. 3H and 5B
and Fig. S4A). BET bromodomain inhibition with JQ1 depleted
BRD4 from chromatin, and this resulted in reduced transcrip-
tion of Pparg and Cebpa. This effect on Pparg and Cebpa ex-
pression also blocked transcription of known downstream target
genes such as Fabp4 (Fig. S4B). Finally, we considered the
possibility that TF genes induced at earlier time points during
L1 adipogenesis (Fig. 2E) are less sensitive to BET inhibition
because they are not controlled by super-enhancers. Analysis of a
previously published dataset of genome-wide binding of MED1—a
constituent of super-enhancers (8)—at 4 h after the start of
L1 differentiation revealed no super-enhancers assigned to Krox20,
Cebpd, and Cebpb genes (Fig. S4C) (7). Collectively, these data
reveal that BET inhibition blocks transcription of super
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Fig. 3. Brd4 is dynamically redistributed to proadipogenic enhancers. (A and
B) Plots of enhancers in preadipocytes (D0; A) and adipocytes (D2; B) ranked by
increasing BRD4 signal in units of reads per million (rpm). Enhancers are de-
fined as regions of BRD4 ChIP-Seq binding not contained in promoters. The
cutoff discriminating typical enhancers from super-enhancers is shown as a
dashed line. (C) Horizontal bar plot of all genomic regions containing a SE
in preadipocytes (D0) or differentiating adipocytes (D2) ranked by log2 change
in BRD4 signal. The x axis shows the log2 fold change in BRD4 signal. Change in
BRD4 levels at SEs are colored by intensity of change (green to red). (D) Hor-
izontal bar plot showing the ratio of TF motif density between gained (D2)
and lost (D0) super-enhancers. Twenty-one TFs are displayed whose motifs
occur more frequently than expected based on dinucleotide background
model. The motifs are ranked by log2 fold change in density between
D2 gained and D0 lost super-enhancers. (E) Consensus sequences of C/EBPβ
(Top) and NR3C1 (Bottom) DNA binding motifs. (F and G) Scatter plot of C/EBPβ
versus BRD4 binding signals (F) or C/EBPδ versus BRD4 signals (G) in L1 cells on
D2 of differentiation. (H and I) Gene tracks of ChIP-Seq signal (rpm/bp) for BRD4,
H3K27ac, C/EBPβ, and PPARγ at the Pparg locus (H) or Ptn (I) locus in 3T3L1 cells
on D0 (Upper) or D2 (Lower) of differentiation.









Adipocyte differentiation requires the coordinated activity of the
master TFs, C/EBPα, and PPARγ. Disruption of their expression
or function in humans profoundly alters metabolism, in part,
through effects on adipocyte differentiation (31). In this study, we
explored the role of chromatin-dependent signal transduction in
this process. We demonstrate that the BET bromodomain-con-
taining protein, BRD4, transduces the adipogenic program through
formation of de novo super-enhancers that drive transcription of
Pparg and Cebpa and promote adipocyte differentiation.
Super or stretch enhancers are clusters of enhancers where
TFs and coactivator proteins are concentrated and drive tran-
scription of genes controlling cell state (8, 9). In this study, we
identified that BRD4 redistributes to de novo super-enhancers in
proximity to genes encoding TFs, including Cebpa and Pparg, in
response to adipocyte differentiation cues. These data build on
prior reports demonstrating that TF hotspots colocalize with
super-enhancers containing MED1 in differentiating L1 cells (7).
Functional interactions between Mediator and BRD4 may par-
tially explain how BRD4 redistributes to these regions (32). In
addition, the colocalization of BRD4 with multiple TF-binding
motifs, as observed in our study, suggests that site-specific
BRD4 redistribution may occur via interactions between
BRD4 and specific DNA-binding TFs. In the context of in-
flammation, biochemical studies have demonstrated that
BRD4 can bind acetylated p65-RelA, implicating this in-
teraction as a possible mechanism for genome-wide redistri-
bution of BRD4 to inflammatory super-enhancers during innate
immune activation (19, 33). Furthermore, a functional relation-
ship between C/EBPβ and BRD4 has been described in NIH
3T3 fibroblasts (14). Overall, these data are consistent with a
model in which lineage-specific TFs activated during adipo-
genesis direct state-specific flux of BRD4 and other coregulators
to de novo super-enhancers that control cell state.
We find that selective depletion of BRD4 from chromatin
impairs adipocyte differentiation. These results occurred in three
models of adipogenesis (3T3L1, 10T1/2, and SVF) in response to
a panel of structurally dissimilar BET bromodomain inhibitors or
siRNA-mediated knockdown of Brd4. Notably, two independent
studies have recently emerged that used BET bromodomain in-
hibition or conditional Brd4 deletion to demonstrate a role for
BETs in adipogenesis (34, 35). The results presented here align
with these reports while also providing additional significant
insights, including the use of CRISPR interference to demon-
strate directly that silencing of individual, BRD4-enriched en-
dogenous enhancer elements at the Pparg locus resulted in
disrupted Pparg expression and adipogenesis. Whether BRD4
enrichment at specific cis-regulatory elements is sufficient to
drive adipogenesis and which elements are required for this will
be of interest to investigate in future studies. Overall, when
considered collectively, these data demonstrate a requirement
for BETs and BRD4 in adipogenesis through collaboration with
lineage determining TFs and may in part explain why systemic
Brd4 haploinsufficient mice have reduced adipose tissue forma-
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Fig. 4. BRD4 binding sites regulate Pparg expression and adipogenesis. (A)
Gene track of ChIP-Seq signal of BRD4 on D2 of L1 differentiation at the
upstream and intragenic Pparg super-enhancer regions (Upper) and bar plot
of PpargmRNA expression (D4 of L1 differentiation) in cells stably expressing
dCas9-KRAB alone or with gRNAs targeting individual enhancer constituent
sites (E1–E6). (Lower) Three unique gRNAs per enhancer site were used in
separate cell lines. (B) Oil red O staining of cells (D7) treated as in A. The
statistical significance of the difference in expression between individual
gRNA and dCas9-KRAB was determined using two-tailed t test. (Magnifica-











































Fig. 5. Transcription of adipogenic master regulatory factors is BET bromo-
domain-dependent. (A) Scatter plot of RNA Pol II ChIP-Seq signal at gene bodies
of all actively transcribed genes in L1 cells on D2 of differentiation versus D2 +
JQ1 (500 nM). (B) Gene tracks of ChIP-Seq signal (rpm/bp) for BRD4 (D2 versus
D2 + JQ1 of differentiation) and RNA Pol II on D0 (Top), D2 (Middle), and D2 +
JQ1 (500 nM, Bottom) of differentiation at the Pparg (B) locus in L1 cells.
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over time, revealing the presence of precise temporal windows
during which enhancer activity is required to regulate distinct
stages of adipocyte differentiation. The muted effect of BET
bromodomain inhibition at later time points may reflect com-
pensation by other coactivators such as MED1 at established su-
per-enhancers, functional cooperativity between multiple TFs
bound at these regions or bromodomain-independent re-
cruitment of BETs to these enhancers (13, 37). Our findings in
adipogenesis extend prior work describing the role of BRD4-
enriched super-enhancers in cell state. In embryonic stem cells
(ESCs) and in certain cancers, super-enhancers regulate expres-
sion of pluripotency factors (8, 17) or oncogenes, respectively (16,
22). In these contexts, BET bromodomain inhibition triggers dif-
ferentiation, growth arrest, and/or cell death (22). The differen-
tiation block by JQ1 in L1 and 10T1/2 cells stands in sharp
contrast to the prodifferentiation effects of BET inhibition in
ESCs and NUT midline carcinoma (17, 22). These differences
highlight how BETs transduce signals controlling the establishment
of specific, TF-driven cell states by coactivating context-specific
enhancer activity to RNA polymerase II.
BET bromodomain inhibitors are a new class of drugs in cancer
therapy now under investigation in human clinical trials. The data
presented herein have implications for this therapeutic approach.
Disruption of BET-occupied enhancers may have adverse conse-
quences in noncancer cellular compartments including adipocytes,
where stimulus-coupled transcription is an essential mechanism
controlling metabolic homeostasis. Furthermore, analysis of BET-
dependent super-enhancer wiring may provide insight into potential
on-target toxicities of pharmacologic BET bromodomain inhibitors
that target cell-state defining genes. Considered more broadly,
understanding the precise mechanisms underlying context-specific,
BET bromodomain-dependent coactivation may deepen our un-
derstanding of the gene regulatory circuits governing tissue-specific
responses in development and diseases outside of cancer.
Experimental Procedures
Animal experiments were approved by Institutional Animal Care and Use
Committee (IACUC) at Harvard Medical School. Adipocyte differentiation
was performed in media supplemented with fetal bovine serum (10%), in-
sulin, dexamethasone, and IBMX. For 10T1/2 cells, 1 nM T3 and 0.125 mM
indomethacin was also included. Summary data are presented as mean ± SEM,
and Student’s t test was used to compare groups. For kinetic gene expression,
ANOVA was conducted. Methods for ChIP-Seq, coimmunoprecipitation,
CRISPRi, RNA preparation, and cell staining are provided in SI Experimental
Procedures.
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